These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 25636086)

  • 21. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
    Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
    Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
    J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
    Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML
    Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection.
    Chen YL; Jeng YM; Chang CN; Lee HJ; Hsu HC; Lai PL; Yuan RH
    Int J Surg; 2014; 12(7):659-65. PubMed ID: 24866078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
    Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
    Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetics: genetics of biliary tract cancer.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2013 Dec; 10(12):692. PubMed ID: 24247265
    [No Abstract]   [Full Text] [Related]  

  • 27. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators.
    Fujimoto A; Totoki Y; Abe T; Boroevich KA; Hosoda F; Nguyen HH; Aoki M; Hosono N; Kubo M; Miya F; Arai Y; Takahashi H; Shirakihara T; Nagasaki M; Shibuya T; Nakano K; Watanabe-Makino K; Tanaka H; Nakamura H; Kusuda J; Ojima H; Shimada K; Okusaka T; Ueno M; Shigekawa Y; Kawakami Y; Arihiro K; Ohdan H; Gotoh K; Ishikawa O; Ariizumi S; Yamamoto M; Yamada T; Chayama K; Kosuge T; Yamaue H; Kamatani N; Miyano S; Nakagama H; Nakamura Y; Tsunoda T; Shibata T; Nakagawa H
    Nat Genet; 2012 May; 44(7):760-4. PubMed ID: 22634756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatocellular carcinoma with persistent hepatitis B virus infection shows unusual downregulation of Ras expression and differential response to Ras mediated signaling.
    Bose S; Sakhuja P; Bezawada L; Agarwal AK; Kazim SN; Khan LA; Sarin SK; Ramakrishna G
    J Gastroenterol Hepatol; 2011 Jan; 26(1):135-44. PubMed ID: 21175807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MYH Y165C and G382D mutations in hepatocellular carcinoma and cholangiocarcinoma patients.
    Baudhuin LM; Roberts LR; Enders FT; Swanson RL; Mettler TA; Aderca I; Stadheim LM; Highsmith WE
    J Cancer Res Clin Oncol; 2006 Mar; 132(3):159-62. PubMed ID: 16292541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Copy number aberrations in combined hepatocellular carcinoma and cholangiocarcinoma.
    You HL; Weng SW; Li SH; Wei YC; Sheu JJ; Chen CM; Huang WT
    Exp Mol Pathol; 2012 Jun; 92(3):281-6. PubMed ID: 22366251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microsatellite alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Koo SH; Ihm CH; Kwon KC; Lee JS; Park JW; Kim JW
    Cancer Genet Cytogenet; 2003 Oct; 146(2):139-44. PubMed ID: 14553948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.
    Chan-On W; Nairismägi ML; Ong CK; Lim WK; Dima S; Pairojkul C; Lim KH; McPherson JR; Cutcutache I; Heng HL; Ooi L; Chung A; Chow P; Cheow PC; Lee SY; Choo SP; Tan IB; Duda D; Nastase A; Myint SS; Wong BH; Gan A; Rajasegaran V; Ng CC; Nagarajan S; Jusakul A; Zhang S; Vohra P; Yu W; Huang D; Sithithaworn P; Yongvanit P; Wongkham S; Khuntikeo N; Bhudhisawasdi V; Popescu I; Rozen SG; Tan P; Teh BT
    Nat Genet; 2013 Dec; 45(12):1474-8. PubMed ID: 24185513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Look into hepatic progenitor cell associated trait: Histological heterogeneity of hepatitis B-related combined hepatocellular-cholangiocarcinoma.
    Cai X; Xiong J; Hu QG; Zhao QD; Wu D; Tang LG; Wan CD; Wei LX
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):873-879. PubMed ID: 29270746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
    Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
    Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
    Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
    Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways.
    Kongpetch S; Jusakul A; Ong CK; Lim WK; Rozen SG; Tan P; Teh BT
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):233-44. PubMed ID: 25966424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arid1a mutation suppresses TGF-β signaling and induces cholangiocarcinoma.
    Guo B; Friedland SC; Alexander W; Myers JA; Wang W; O'Dell MR; Getman M; Whitney-Miller CL; Agostini-Vulaj D; Huber AR; Mello SS; Vertino PM; Land HK; Steiner LA; Hezel AF
    Cell Rep; 2022 Aug; 40(9):111253. PubMed ID: 36044839
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Ho DWH; Chan LK; Chiu YT; Xu IMJ; Poon RTP; Cheung TT; Tang CN; Tang VWL; Lo ILO; Lam PWY; Yau DTW; Li MX; Wong CM; Ng IOL
    Gut; 2017 Aug; 66(8):1496-1506. PubMed ID: 27974549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
    Cevik D; Yildiz G; Ozturk M
    World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetics of hepatobiliary carcinogenesis.
    Nault JC; Zucman-Rossi J
    Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.